(from the November/December 2020 ACP Internist)
By Ryan DuBosar
While effective medications to treat opioid addiction are available in primary care, few physicians prescribe buprenorphine or naltrexone, and few would obtain the Drug Enforcement Administration (DEA) waiver to prescribe buprenorphine.
Rates of opioid addiction treatment in primary care remain distressingly low in the United States. Fixing that might require a wholesale reimagining of how opioid use disorders should be viewed as well as managed.
Read the full article in ACP Internist.
ACP Internist provides news and information for internists about the practice of medicine and reports on the policies, products, and activities of ACP.
Back to the December 2020 issue of ACP IMpact